Scott A. Irwin, MD, PhD, of Cedars-Sinai’s Samuel Oschin Comprehensive Cancer Institute, discusses delirium—its definition, prevalence, consequences, assessment, and management.
Jennifer S. Temel, MD, of Massachusetts General Hospital, discusses increasing prognostic uncertainty in light of targeted treatments and immunotherapies, and the difficulty predicting who will benefit.
Joseph A. Greer, PhD, of Massachusetts General Hospital, discusses the development of a mobile application to address treatment adherence and symptoms (Abstract 104).
Charles D. Blanke, MD, of the Oregon Health & Science University and Southwest Oncology Group, discusses the nearly 20 years’ experience with Oregon’s Death With Dignity (DWD) Act, a voter initiative that led to the first such law enacted in the United States (Abstract 44).
Tracy A. Balboni, MD, MPH, of the Dana-Farber Cancer Institute, talks about how to preserve quality of life in the presence of complex spinal lesions, including novel ways to assess spinal instability and treat metastases.
Stephen T. Sonis, DMD, DMSc, of Dana-Farber Cancer Institute, discusses the epidemiology, pathogenesis, and scope of oral complications of radiation therapy.
